Occult HBV infection among Egyptian hepatocellular carcinoma patients

Virology Journal

Volumn 8, Issue , 2011, Pages

  Hassan, Zeinab K ^a,b   Hafez, Mohamed M ^a,c   Mansor, Tarek M ^a   Zekri, Abdel Rahman N ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PRIMER DNA; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EGYPT; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS GENOME; BLOOD; GENETICS; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; LIVER; LIVER TUMOR; MIDDLE AGED; PHYSIOLOGY; VIROLOGY;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; EGYPT; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 79952104949     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-90     Document Type: Article

References (47)

1. Hepatocellular carcinoma: an epidemiologic view. HB El-Serag, J Clin Gastroenterol 2002 35 5 Suppl 2 72 78 10.1097/00004836-200211002-00002 12394209
2. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. RF Velazquez M Rodriguez CA Navascues A Linares R Perez NG Sotorrios I Martinez L Rodrigo, Hepatology 2003 37 3 520 527 10.1053/jhep.2003.50093 12601348 (Pubitemid 36258772)
3. Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience. A Rahman El-Zayadi H Abaza S Shawky MK Mohamed OE Selim HM Badran, Hepatol Res 2001 19 2 170 179 10.1016/S1386-6346(00)00105-4 11164741 (Pubitemid 32094288)
4. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. K Ohata K Hamasaki K Toriyama H Ishikawa K Nakao K Eguchi, J Gastroenterol Hepatol 2004 19 6 670 675 10.1111/j.1440-1746.2004.03360.x 15151623 (Pubitemid 38858201)
5. Genotyping of Tunisian hepatitis B virus isolates based on the sequencing of preS2 and S regions. I Borchani-Chabchoub A Gargouri R Mokdad-Gargouri, Microbes Infect 2000 2 6 607 612 10.1016/S1286-4579(00)00365-8 10884611 (Pubitemid 30412571)
6. Phylogenetic analysis of new hepatitis B virus isolates from Nigeria supports endemicity of genotype E in West Africa. SO Odemuyiwa MN Mulders OI Oyedele SO Ola GN Odaibo DO Olaleye CP Muller, J Med Virol 2001 65 3 463 469 10.1002/jmv.2058 11596079 (Pubitemid 32959070)
7. Chronic hepatitis B. AS Lok, N Engl J Med 2002 346 22 1682 1683 10.1056/NEJM200205303462202 12037146
8. Prevalence of hepatitis B and C in Egypt and Africa. MA Attia, Antivir Ther 1998 3 Suppl 3 1 9 10726051 (Pubitemid 28528317)
9. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. J Hou Z Wang J Cheng Y Lin GK Lau J Sun F Zhou J Waters P Karayiannis K Luo, Hepatology 2001 34 5 1027 1034 10.1053/jhep.2001.28708 11679975 (Pubitemid 33032039)
10. Occult hepatitis B virus infection and its clinical implications. KQ Hu, J Viral Hepat 2002 9 4 243 257 10.1046/j.1365-2893.2002.00344.x 12081601
11. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. C Brechot F Degos C Lugassy V Thiers S Zafrani D Franco H Bismuth C Trepo JP Benhamou J Wands, et al. N Engl J Med 1985 312 5 270 276 10.1056/NEJM198501313120503 2981408 (Pubitemid 15199365)
12. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. P Paterlini G Gerken E Nakajima S Terre A D'Errico W Grigioni B Nalpas D Franco J Wands M Kew, et al. N Engl J Med 1990 323 2 80 85 10.1056/NEJM199007123230202 2359427 (Pubitemid 20221643)
13. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? C Brechot V Thiers D Kremsdorf B Nalpas S Pol P Paterlini-Brechot, Hepatology 2001 34 1 194 203 10.1053/jhep.2001.25172 11431751 (Pubitemid 32591500)
14. Epidemiology and Prevention of Hepatitis B Virus Infection. J Hou Z Liu F Gu, Int J Med Sci 2005 2 1 50 57 15968340 (Pubitemid 40935433)
15. Hepatitis B virus genotypes, phylogeny and occult infection in a region with a high incidence of hepatocellular carcinoma in China. ZL Fang H Zhuang XY Wang XM Ge TJ Harrison, World J Gastroenterol 2004 10 22 3264 3268 15484297 (Pubitemid 39585462)
16. Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. L Kazemi-Shirazi D Petermann C Muller, J Hepatol 2000 33 5 785 790 10.1016/S0168-8278(00)80311-6 11097488
17. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. H Naito S Hayashi K Abe, J Clin Microbiol 2001 39 1 362 364 10.1128/JCM.39.1.362-364.2001 11136801 (Pubitemid 32059621)
18. Hepatitis B virus (HBV) genotypes in Egyptian pediatric cancer patients with acute and chronic active HBV infection. AR Zekri MM Hafez NI Mohamed ZK Hassan MH El-Sayed MM Khaled T Mansour, Virol J 2007 4 74 10.1186/1743-422X-4-74 17631684
19. Genetic profile of Egyptian hepatocellular-carcinoma associated with hepatitis C virus Genotype 4 by 15 K cDNA microarray: preliminary study. AR Zekri MM Hafez AA Bahnassy ZK Hassan T Mansour MM Kamal HM Khaled, BMC Res Notes 2008 1 106 10.1186/1756-0500-1-106 18959789
20. Clinical impact of occult HBV infections. I Chemin C Trepo, J Clin Virol 2005 34 Suppl 1 15 21 10.1016/S1386-6532(05)80005-8 16461218
21. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. L Xunrong AW Yan R Liang GK Lau, Rev Med Virol 2001 11 5 287 299 10.1002/rmv.322 11590667 (Pubitemid 33009970)
22. Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. K Ishiga T Kawatani T Suou F Tajima H Omura Y Idobe H Kawasaki, Int J Hematol 2001 73 1 115 118 10.1007/BF02981912 11372746 (Pubitemid 33758848)
23. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. CK Hui J Sun WY Au AK Lie YH Yueng HY Zhang NP Lee JL Hou R Liang GK Lau, J Hepatol 2005 42 6 813 819 10.1016/j.jhep.2005.01. 018 15885351 (Pubitemid 40693197)
24. Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission. AR El-Zayadi EH Ibrahim HM Badran A Saeid NA Moneib MA Shemis RM Abdel-Sattar AM Ahmady A El-Nakeeb, Transfus Med 2008 18 1 55 61 10.1111/j.1365-3148.2007.00806.x 18279193 (Pubitemid 351239313)
25. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. T Pollicino G Squadrito G Cerenzia I Cacciola G Raffa A Craxi F Farinati G Missale A Smedile C Tiribelli, et al. Gastroenterology 2004 126 1 102 110 10.1053/j.gastro.2003.10.048 14699492 (Pubitemid 38040728)
26. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. JT Wang TH Wang JC Sheu LN Shih JT Lin DS Chen, J Infect Dis 1991 163 2 397 399 1988524
27. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. F Besisik C Karaca F Akyuz S Horosanli D Onel S Badur MS Sever A Danalioglu K Demir S Kaymakoglu, et al. J Hepatol 2003 38 4 506 510 10.1016/S0168-8278(02)00457-9 12663244 (Pubitemid 36399255)
28. High prevalence of occult hepatitis B in Baltimore injection drug users. M Torbenson R Kannangai J Astemborski SA Strathdee D Vlahov DL Thomas, Hepatology 2004 39 1 51 57 10.1002/hep.20025 14752822 (Pubitemid 38461466)
29. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. R Idilman M Arat E Soydan M Toruner I Soykan H Akbulut O Arslan M Ozcan AR Turkyilmaz M Bozdayi, et al. J Viral Hepat 2004 11 2 141 147 10.1046/j.1365-2893.2003.00479.x 14996349 (Pubitemid 38365765)
30. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Blackberg K Kidd-Ljunggren, J Hepatol 2000 33 6 992 997 10.1016/S0168-8278(00)80134-8 11131464
31. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. H Marusawa S Uemoto M Hijikata Y Ueda K Tanaka K Shimotohno T Chiba, Hepatology 2000 31 2 488 495 10.1002/hep.510310232 10655275 (Pubitemid 30078617)
32. Inapparent "wild-type" and "e-minus variant" HBV infection in patients with HCV-related chronic hepatitis. MA Sardo G Rodino S Brancatelli M Pernice S Campo G Squadrito F Russo G Raimondo, Liver 1994 14 5 241 244 7997082
33. HBV genome integration and genetic instability in HBsAg-negative and anti-HCV-positive hepatocellular carcinoma in Japan. Y Matsuzaki T Chiba T Hadama H Asaoka M Doy J Shoda N Tanaka M Kinoshita, Cancer Lett 1997 119 1 53 61 10.1016/S0304-3835(97)00249-8 18372522 (Pubitemid 27464665)
34. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. K Kim KH Kim HH Kim J Cheong, Biochem J 2008 416 2 219 230 10.1042/BJ20081336 18782084
35. Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. A El-Sherif M Abou-Shady H Abou-Zeid A Elwassief A Elbahrawy Y Ueda T Chiba AM Hosney, J Gastroenterol 2009 44 4 359 364 10.1007/s00535-009-0020-3 19271112
36. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. SH Kleinman MC Kuhns DS Todd SA Glynn A McNamara A DiMarco MP Busch, Transfusion 2003 43 6 696 704 10.1046/j.1537-2995.2003.00391.x 12757519 (Pubitemid 36629113)
37. Occult hepatitis B virus infection. JP Allain, Transfus Clin Biol 2004 11 1 18 25 10.1016/j.tracli.2003.11.007 14980545
38. Hepatocellular carcinoma. JM Llovet A Burroughs J Bruix, Lancet 2003 362 9399 1907 1917 10.1016/S0140-6736(03)14964-1 14667750 (Pubitemid 37518510)
39. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. I Cacciola T Pollicino G Squadrito G Cerenzia ME Orlando G Raimondo, N Engl J Med 1999 341 1 22 26 10.1056/NEJM199907013410104 10387938 (Pubitemid 29293716)
40. Overt and hidden coinfection with hepatitis B and C viruses in chronic liver disease and porphyria cutanea tarda. J Stransky L Malina B Cieslarova J Stritesky I Putova J Horak, Acta Virol 2000 44 1 23 28 10989688 (Pubitemid 30662582)
41. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. R Fukuda N Ishimura M Niigaki S Hamamoto S Satoh S Tanaka Y Kushiyama Y Uchida S Ihihara S Akagi, et al. J Med Virol 1999 58 3 201 207 10.1002/(SICI)1096-9071(199907)58:3<201::AID-JMV3>3.0.CO;2-2 10447413 (Pubitemid 29278020)
42. The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. K Nirei M Kaneko M Moriyama Y Arakawa, Intervirology 2000 43 2 95 101 10.1159/000025030 10971127
43. Hepatitis B virus DNA detected by PCR in sera and liver tissues of Chinese patients with chronic liver diseases. YY Zhang LS Guo L Li YD Zhang LJ Hao BG Hansson E Nordenfelt, Chin Med J (Engl) 1993 106 1 7 12 8504690
44. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. K Ikeda S Saitoh I Koida Y Arase A Tsubota K Chayama H Kumada M Kawanishi, Hepatology 1993 18 1 47 53 10.1002/hep.1840180109 7686879 (Pubitemid 23193616)
45. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. TI Huo JC Wu PC Lee GY Chau WY Lui SH Tsay LT Ting FY Chang SD Lee, Hepatology 1998 28 1 231 236 10.1002/hep.510280130 9657117
46. [Detection of HBV-DNA from hepatocellular carcinoma by polymerase chain reaction]. M Takeuchi E Okamoto J Fujimoto, Nippon Rinsho 1995 53 Suppl Pt 2 718 722 12442473
47. Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries. X Ding YN Park TC Taltavull SN Thung X Jin Y Jin NS Trung Y Edamoto T Sata K Abe, Jpn J Infect Dis 2003 56 1 12 18 12711820 (Pubitemid 36626515)